{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:07:26Z","timestamp":1787764046242,"version":"build-2784847793"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40265-020-01364-2","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T13:26:17Z","timestamp":1595942777000},"page":"1537-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs"],"prefix":"10.1007","volume":"80","author":[{"given":"N. R.","family":"Fuggle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Al-Daghri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Diez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Prieto-Alhambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tremollieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"issue":"10","key":"1364_CR1","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s40520-019-01282-8","volume":"31","author":"W Xia","year":"2019","unstructured":"Xia W, Cooper C, Li M, et al. East meets West: current practices and policies in the management of musculoskeletal aging. Aging Clin Exp Res. 2019;31(10):1351\u201373. https:\/\/doi.org\/10.1007\/s40520-019-01282-8.","journal-title":"Aging Clin Exp Res"},{"issue":"6","key":"1364_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40520-019-01150-5","volume":"31","author":"M Chandran","year":"2019","unstructured":"Chandran M, Tay D, Mithal A. Supplemental calcium intake in the aging individual: implications on skeletal and cardiovascular health. Aging Clin Exp Res. 2019;31(6):765\u201381. https:\/\/doi.org\/10.1007\/s40520-019-01150-5.","journal-title":"Aging Clin Exp Res"},{"issue":"8","key":"1364_CR3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archinte.166.8.869","volume":"166","author":"RL Prince","year":"2006","unstructured":"Prince RL, Devine A, Dhaliwal SS, et al. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med. 2006;166(8):869\u201375. https:\/\/doi.org\/10.1001\/archinte.166.8.869.","journal-title":"Arch Intern Med"},{"issue":"7638","key":"1364_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bmj.39440.525752.BE","volume":"336","author":"MJ Bolland","year":"2008","unstructured":"Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008;336(7638):262\u20136. https:\/\/doi.org\/10.1136\/bmj.39440.525752.BE.","journal-title":"BMJ"},{"issue":"7","key":"1364_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/circulationaha.106.673491","volume":"115","author":"J Hsia","year":"2007","unstructured":"Hsia J, Heiss G, Ren H, et al. Calcium\/vitamin D supplementation and cardiovascular events. Circulation. 2007;115(7):846\u201354. https:\/\/doi.org\/10.1161\/circulationaha.106.673491.","journal-title":"Circulation"},{"key":"1364_CR6","doi-asserted-by":"publisher","first-page":"c3691","DOI":"10.1136\/bmj.c3691","volume":"341","author":"MJ Bolland","year":"2010","unstructured":"Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691. https:\/\/doi.org\/10.1136\/bmj.c3691.","journal-title":"BMJ"},{"key":"1364_CR7","doi-asserted-by":"publisher","first-page":"d2040","DOI":"10.1136\/bmj.d2040","volume":"342","author":"MJ Bolland","year":"2011","unstructured":"Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women\u2019s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040. https:\/\/doi.org\/10.1136\/bmj.d2040.","journal-title":"BMJ"},{"key":"1364_CR8","doi-asserted-by":"publisher","unstructured":"Harvey NC, Biver E, Kaufman JM et al. (2017) The role of calcium supplementation in healthy musculoskeletal ageing: an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). 28 (2):447-462. https:\/\/doi.org\/10.1007\/s00198-016-3773-6.","DOI":"10.1007\/s00198-016-3773-6"},{"issue":"2","key":"1364_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-012-2224-2","volume":"24","author":"RL Prentice","year":"2013","unstructured":"Prentice RL, Pettinger MB, Jackson RD, et al. Health risks and benefits from calcium and vitamin D supplementation: Women\u2019s Health Initiative clinical trial and cohort study. Osteoporos Int. 2013;24(2):567\u201380. https:\/\/doi.org\/10.1007\/s00198-012-2224-2.","journal-title":"Osteoporos Int"},{"issue":"11","key":"1364_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1089\/jwh.2013.4270","volume":"22","author":"JA Cauley","year":"2013","unstructured":"Cauley JA, Chlebowski RT, Wactawski-Wende J, et al. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women\u2019s Health Initiative. J Women\u2019s Health (2002). 2013;22(11):915\u201329. https:\/\/doi.org\/10.1089\/jwh.2013.4270.","journal-title":"J Women\u2019s Health (2002)"},{"issue":"1","key":"1364_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/jbmr.2311","volume":"30","author":"JR Lewis","year":"2015","unstructured":"Lewis JR, Radavelli-Bagatini S, Rejnmark L, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res. 2015;30(1):165\u201375. https:\/\/doi.org\/10.1002\/jbmr.2311.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1364_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jbmr.3375","volume":"33","author":"NC Harvey","year":"2018","unstructured":"Harvey NC, D\u2019Angelo S, Paccou J, et al. Calcium and vitamin D supplementation are not associated with risk of incident ischemic cardiac events or death: findings from the UK Biobank Cohort. J Bone Miner Res. 2018;33(5):803\u201311. https:\/\/doi.org\/10.1002\/jbmr.3375.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1364_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/gme.0b013e3181d683b5","volume":"17","author":"JE Manson","year":"2010","unstructured":"Manson JE, Allison MA, Carr JJ, et al. Calcium\/vitamin D supplementation and coronary artery calcification in the Women\u2019s Health Initiative. Menopause. 2010;17(4):683\u201391. https:\/\/doi.org\/10.1097\/gme.0b013e3181d683b5.","journal-title":"Menopause"},{"key":"1364_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2019.1649219","author":"C Yang","year":"2019","unstructured":"Yang C, Shi X, Xia H, et al. The evidence and controversy between dietary calcium intake and calcium supplementation and the risk of cardiovascular disease: a systematic review and meta-analysis of cohort studies and randomized controlled trials. J Am Coll Nutr. 2019. https:\/\/doi.org\/10.1080\/07315724.2019.1649219.","journal-title":"J Am Coll Nutr"},{"issue":"6","key":"1364_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3945\/an.112.002899","volume":"3","author":"RP Heaney","year":"2012","unstructured":"Heaney RP, Kopecky S, Maki KC, et al. A review of calcium supplements and cardiovascular disease risk. Adv Nutr. 2012;3(6):763\u201371. https:\/\/doi.org\/10.3945\/an.112.002899.","journal-title":"Adv Nutr"},{"key":"1364_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd010037.pub2","author":"G Cormick","year":"2015","unstructured":"Cormick G, Ciapponi A, Cafferata ML, et al. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.cd010037.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1364_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00002512-200421010-00002","volume":"21","author":"IR Reid","year":"2004","unstructured":"Reid IR. Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications. Drugs Aging. 2004;21(1):7\u201317. https:\/\/doi.org\/10.2165\/00002512-200421010-00002.","journal-title":"Drugs Aging"},{"key":"1364_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000486060","volume":"50","author":"D Goltzman","year":"2018","unstructured":"Goltzman D, Mannstadt M, Marcocci C. Physiology of the calcium-parathyroid hormone-vitamin D axis. Front Horm Res. 2018;50:1\u201313. https:\/\/doi.org\/10.1159\/000486060.","journal-title":"Front Horm Res"},{"issue":"1","key":"1364_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1364_CR20","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"Pepe J, Cipriani C, Sonato C, et al. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol. 2017;177(6):R297\u2013308. https:\/\/doi.org\/10.1530\/EJE-17-0485.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1364_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jelectrocard.2010.06.004","volume":"43","author":"P Bjerregaard","year":"2010","unstructured":"Bjerregaard P, Nallapaneni H, Gussak I. Short QT interval in clinical practice. J Electrocardiol. 2010;43(5):390\u20135. https:\/\/doi.org\/10.1016\/j.jelectrocard.2010.06.004.","journal-title":"J Electrocardiol"},{"issue":"6","key":"1364_CR22","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1210\/jc.2014-4551","volume":"100","author":"D Durup","year":"2015","unstructured":"Durup D, J\u00f8rgensen HL, Christensen J, et al. A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality: the CopD study. J Clin Endocrinol Metab. 2015;100(6):2339\u201346. https:\/\/doi.org\/10.1210\/jc.2014-4551.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1364_CR23","doi-asserted-by":"publisher","first-page":"e88767","DOI":"10.1371\/journal.pone.0088767","volume":"9","author":"T Ellam","year":"2014","unstructured":"Ellam T, Hameed A, ul Haque R, et al. Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice. PLoS One. 2014;9(2):e88767. https:\/\/doi.org\/10.1371\/journal.pone.0088767.","journal-title":"PLoS One"},{"key":"1364_CR24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz212","author":"EO Billington","year":"2019","unstructured":"Billington EO, Burt LA, Rose MS, et al. Safety of high-dose vitamin D supplementation: secondary analysis of a randomized controlled trial. J Clin Endocrinol Metab. 2019. https:\/\/doi.org\/10.1210\/clinem\/dgz212.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1364_CR25","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00198-019-05098-0","volume":"30","author":"R Bouillon","year":"2019","unstructured":"Bouillon R. Vitamin D and cardiovascular disorders. Osteoporos Int. 2019;30(11):2167\u201381. https:\/\/doi.org\/10.1007\/s00198-019-05098-0.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1364_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/ajcn\/nqy078","volume":"107","author":"KM Swart","year":"2018","unstructured":"Swart KM, Lips P, Brouwer IA, et al. Effects of vitamin D supplementation on markers for cardiovascular disease and type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. AM J Clin Nutr. 2018;107(6):1043\u201353. https:\/\/doi.org\/10.1093\/ajcn\/nqy078.","journal-title":"AM J Clin Nutr"},{"issue":"1","key":"1364_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1809944","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1809944.","journal-title":"N Engl J Med"},{"issue":"6","key":"1364_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1001\/jamacardio.2017.0175","volume":"2","author":"R Scragg","year":"2017","unstructured":"Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial. JAMA Cardiol. 2017;2(6):608\u201316. https:\/\/doi.org\/10.1001\/jamacardio.2017.0175.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"1364_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jamacardio.2019.1870","volume":"4","author":"M Barbarawi","year":"2019","unstructured":"Barbarawi M, Kheiri B, Zayed Y, et al. Vitamin D supplementation and cardiovascular disease risks in more than 83 000 individuals in 21 randomized clinical trials: a meta-analysis. JAMA Cardiol. 2019;4(8):765\u201375. https:\/\/doi.org\/10.1001\/jamacardio.2019.1870.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1364_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40520-018-1109-4","volume":"31","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, et al. Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res. 2019;31(1):15\u20137. https:\/\/doi.org\/10.1007\/s40520-018-1109-4.","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"1364_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11154-017-9417-0","volume":"18","author":"MR Gr\u00fcbler","year":"2017","unstructured":"Gr\u00fcbler MR, M\u00e4rz W, Pilz S, et al. Vitamin-D concentrations, cardiovascular risk and events\u2014a review of epidemiological evidence. Rev Endocr Metab Disord. 2017;18(2):259\u201372. https:\/\/doi.org\/10.1007\/s11154-017-9417-0.","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"1364_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/gme.0000000000000519","volume":"23","author":"L Zhu","year":"2016","unstructured":"Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461\u201370. https:\/\/doi.org\/10.1097\/gme.0000000000000519.","journal-title":"Menopause"},{"issue":"4","key":"1364_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-85-4-447","volume":"85","author":"WB Kannel","year":"1976","unstructured":"Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85(4):447\u201352. https:\/\/doi.org\/10.7326\/0003-4819-85-4-447.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1364_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","volume":"16","author":"CM Rivera","year":"2009","unstructured":"Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause (New York, NY). 2009;16(1):15\u201323. https:\/\/doi.org\/10.1097\/gme.0b013e31818888f7.","journal-title":"Menopause (New York, NY)"},{"issue":"4","key":"1364_CR35","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1161\/STROKEAHA.108.542993","volume":"40","author":"LD Lisabeth","year":"2009","unstructured":"Lisabeth LD, Beiser AS, Brown DL, et al. Age at natural menopause and risk of ischemic stroke: the Framingham Heart Study. Stroke. 2009;40(4):1044\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.108.542993.","journal-title":"Stroke"},{"issue":"5","key":"1364_CR36","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.metabol.2016.01.004","volume":"65","author":"SS Bassuk","year":"2016","unstructured":"Bassuk SS, Manson JE. The Timing Hypothesis: do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metab Clin Exp. 2016;65(5):794\u2013803. https:\/\/doi.org\/10.1016\/j.metabol.2016.01.004.","journal-title":"Metab Clin Exp"},{"issue":"2","key":"1364_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/clc.22891","volume":"41","author":"RC Chester","year":"2018","unstructured":"Chester RC, Kling JM, Manson JE. What the Women\u2019s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol. 2018;41(2):247\u201352. https:\/\/doi.org\/10.1002\/clc.22891.","journal-title":"Clin Cardiol"},{"issue":"6","key":"1364_CR38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","volume":"19","author":"MA Hern\u00e1n","year":"2008","unstructured":"Hern\u00e1n MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (Cambridge, Mass). 2008;19(6):766\u201379. https:\/\/doi.org\/10.1097\/EDE.0b013e3181875e61.","journal-title":"Epidemiology (Cambridge, Mass)"},{"issue":"3","key":"1364_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/ajcn\/nqy078","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321\u201333. https:\/\/doi.org\/10.1093\/ajcn\/nqy078.","journal-title":"JAMA"},{"issue":"1","key":"1364_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.291.1.47","volume":"291","author":"AL Hersh","year":"2004","unstructured":"Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47\u201353. https:\/\/doi.org\/10.1001\/jama.291.1.47.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"1364_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/13697137.2012.669332","volume":"15","author":"JA Simon","year":"2012","unstructured":"Simon JA. What\u2019s new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Clim J Int Menopause Soc. 2012;15(Suppl 1):3\u201310. https:\/\/doi.org\/10.3109\/13697137.2012.669332.","journal-title":"Clim J Int Menopause Soc"},{"issue":"13","key":"1364_CR42","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","volume":"292","author":"M Cushman","year":"2004","unstructured":"Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573\u201380. https:\/\/doi.org\/10.1001\/jama.292.13.1573.","journal-title":"JAMA"},{"issue":"20","key":"1364_CR43","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.289.20.2673","volume":"289","author":"S Wassertheil-Smoller","year":"2003","unstructured":"Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women\u2019s Health Initiative: a randomized trial. JAMA. 2003;289(20):2673\u201384. https:\/\/doi.org\/10.1001\/jama.289.20.2673.","journal-title":"JAMA"},{"issue":"6","key":"1364_CR44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa030808","volume":"349","author":"JE Manson","year":"2003","unstructured":"Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523\u201334. https:\/\/doi.org\/10.1056\/NEJMoa030808.","journal-title":"N Engl J Med"},{"issue":"7","key":"1364_CR45","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/archinte.166.7.772","volume":"166","author":"JD Curb","year":"2006","unstructured":"Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166(7):772\u201380. https:\/\/doi.org\/10.1001\/archinte.166.7.772.","journal-title":"Arch Intern Med"},{"issue":"20","key":"1364_CR46","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1161\/CIRCULATIONAHA.105.594077","volume":"113","author":"SL Hendrix","year":"2006","unstructured":"Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women\u2019s Health Initiative. Circulation. 2006;113(20):2425\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.594077.","journal-title":"Circulation"},{"issue":"13","key":"1364_CR47","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","volume":"297","author":"JE Rossouw","year":"2007","unstructured":"Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465\u201377. https:\/\/doi.org\/10.1001\/jama.297.13.1465.","journal-title":"JAMA"},{"issue":"7 Suppl 1","key":"1364_CR48","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1210\/jc.2009-2509","volume":"95","author":"RJ Santen","year":"2010","unstructured":"Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1\u201366. https:\/\/doi.org\/10.1210\/jc.2009-2509.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1364_CR49","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/s0008-6363(01)00466-7","volume":"53","author":"TS Mikkola","year":"2002","unstructured":"Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53(3):605\u201319. https:\/\/doi.org\/10.1016\/s0008-6363(01)00466-7.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1364_CR50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/13697137.2012.656401","volume":"15","author":"HN Hodis","year":"2012","unstructured":"Hodis HN, Collins P, Mack WJ, et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Clim J Int Menopause Soc. 2012;15(3):217\u201328. https:\/\/doi.org\/10.3109\/13697137.2012.656401.","journal-title":"Clim J Int Menopause Soc"},{"issue":"4","key":"1364_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.7326\/M14-0353","volume":"161","author":"SM Harman","year":"2014","unstructured":"Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249\u201360. https:\/\/doi.org\/10.7326\/M14-0353.","journal-title":"Ann Intern Med"},{"issue":"13","key":"1364_CR52","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","volume":"374","author":"HN Hodis","year":"2016","unstructured":"Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1505241.","journal-title":"N Engl J Med"},{"issue":"2","key":"1364_CR53","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","volume":"19","author":"RJ Baber","year":"2016","unstructured":"Baber RJ, Panay N, Fenton A, et al. 2016 IMS recommendations on women\u2019s midlife health and menopause hormone therapy. Clim J Int Menopause Soc. 2016;19(2):109\u201350. https:\/\/doi.org\/10.3109\/13697137.2015.1129166.","journal-title":"Clim J Int Menopause Soc"},{"issue":"6","key":"1364_CR54","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/gme.0000000000000665","volume":"23","author":"M Canonico","year":"2016","unstructured":"Canonico M, Scarabin PY. Oral versus transdermal estrogens and venous thromboembolism in postmenopausal women: what is new since 2003? Menopause. 2016;23(6):587\u20138. https:\/\/doi.org\/10.1097\/gme.0000000000000665.","journal-title":"Menopause"},{"key":"1364_CR55","doi-asserted-by":"publisher","first-page":"k4810","DOI":"10.1136\/bmj.k4810","volume":"364","author":"Y Vinogradova","year":"2019","unstructured":"Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. https:\/\/doi.org\/10.1136\/bmj.k4810.","journal-title":"BMJ"},{"issue":"3","key":"1364_CR56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3109\/13697137.2011.570590","volume":"14","author":"DW Sturdee","year":"2011","unstructured":"Sturdee DW, Pines A, International Menopause Society Writing G, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Clim J Int Menopause Soc. 2011;14(3):302\u201320. https:\/\/doi.org\/10.3109\/13697137.2011.570590.","journal-title":"Clim J Int Menopause Soc"},{"issue":"9","key":"1364_CR57","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMp1514242","volume":"374","author":"JE Manson","year":"2016","unstructured":"Manson JE, Kaunitz AM. Menopause management\u2013getting clinical care back on track. N Engl J Med. 2016;374(9):803\u20136. https:\/\/doi.org\/10.1056\/NEJMp1514242.","journal-title":"N Engl J Med"},{"issue":"3","key":"1364_CR58","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/01.aog.0000114986.14806.37","volume":"103","author":"J Yates","year":"2004","unstructured":"Yates J, Barrett-Connor E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol. 2004;103(3):440\u20136. https:\/\/doi.org\/10.1097\/01.aog.0000114986.14806.37.","journal-title":"Obstet Gynecol"},{"key":"1364_CR59","unstructured":"Menopause: diagnosis and management; NG23. National Institute for Health and Care Excellence, London. 2015."},{"issue":"7","key":"1364_CR60","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa0800743","volume":"359","author":"SR Cummings","year":"2008","unstructured":"Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa0800743.","journal-title":"N Engl J Med"},{"issue":"18","key":"1364_CR61","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","volume":"279","author":"BW Walsh","year":"1998","unstructured":"Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279(18):1445\u201351. https:\/\/doi.org\/10.1001\/jama.279.18.1445.","journal-title":"JAMA"},{"issue":"3","key":"1364_CR62","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.maturitas.2005.05.006","volume":"53","author":"M Gol","year":"2006","unstructured":"Gol M, Akan P, Dogan E, et al. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas. 2006;53(3):252\u20139. https:\/\/doi.org\/10.1016\/j.maturitas.2005.05.006.","journal-title":"Maturitas"},{"issue":"2","key":"1364_CR63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2362.2007.01905.x","volume":"38","author":"L Nanetti","year":"2008","unstructured":"Nanetti L, Camilletti A, Francucci CM, et al. Role of raloxifene on platelet metabolism and plasma lipids. Eur J Clin Invest. 2008;38(2):117\u201325. https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01905.x.","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"1364_CR64","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3109\/09513590.2013.788628","volume":"29","author":"F Grover-P\u00e1ez","year":"2013","unstructured":"Grover-P\u00e1ez F, Zavalza-G\u00f3mez AB, Anaya-Prado R. Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women. Gynecol Endocrinol. 2013;29(7):674\u20137. https:\/\/doi.org\/10.3109\/09513590.2013.788628.","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"1364_CR65","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1210\/jc.2002-021557","volume":"88","author":"N Colacurci","year":"2003","unstructured":"Colacurci N, Manzella D, Fornaro F, et al. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab. 2003;88(5):2135\u201340. https:\/\/doi.org\/10.1210\/jc.2002-021557.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1364_CR66","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1067\/mob.2003.299","volume":"188","author":"A Cagnacci","year":"2003","unstructured":"Cagnacci A, Zanni AL, Volpe A. Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study. Am J Obstet Gynecol. 2003;188(5):1278\u201382. https:\/\/doi.org\/10.1067\/mob.2003.299.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1364_CR67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1160\/TH07-07-0468","volume":"99","author":"J Adomaityte","year":"2008","unstructured":"Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost. 2008;99(2):338\u201342.","journal-title":"Thromb Haemost"},{"issue":"8","key":"1364_CR68","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1056\/NEJMoa0808692","volume":"362","author":"SR Cummings","year":"2010","unstructured":"Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686\u201396. https:\/\/doi.org\/10.1056\/NEJMoa0808692.","journal-title":"N Engl J Med"},{"issue":"7","key":"1364_CR69","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jama.287.7.847","volume":"287","author":"E Barrett-Connor","year":"2002","unstructured":"Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287(7):847\u201357. https:\/\/doi.org\/10.1001\/jama.287.7.847.","journal-title":"JAMA"},{"issue":"4","key":"1364_CR70","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.amjcard.2005.09.083","volume":"97","author":"K Ensrud","year":"2006","unstructured":"Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol. 2006;97(4):520\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2005.09.083.","journal-title":"Am J Cardiol"},{"issue":"2","key":"1364_CR71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125\u201337. https:\/\/doi.org\/10.1056\/NEJMoa062462.","journal-title":"N Engl J Med"},{"issue":"17","key":"1364_CR72","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1161\/CIRCULATIONAHA.109.924571","volume":"122","author":"K Ensrud","year":"2010","unstructured":"Ensrud K, LaCroix A, Thompson JR, et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation. 2010;122(17):1716\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.924571.","journal-title":"Circulation"},{"issue":"1","key":"1364_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/ENDO:23:1:01","volume":"23","author":"SI McFarlane","year":"2004","unstructured":"McFarlane SI, Muniyappa R, Shin JJ, et al. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine. 2004;23(1):1\u201310. https:\/\/doi.org\/10.1385\/ENDO:23:1:01.","journal-title":"Endocrine"},{"issue":"9","key":"1364_CR74","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1191\/0961203305lu2219oa","volume":"14","author":"M Bevilacqua","year":"2005","unstructured":"Bevilacqua M, Dominguez LJ, Rosini S, et al. Bisphosphonates and atherosclerosis: why? Lupus. 2005;14(9):773\u20139. https:\/\/doi.org\/10.1191\/0961203305lu2219oa.","journal-title":"Lupus"},{"issue":"4","key":"1364_CR75","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0021-9150(77)90161-7","volume":"27","author":"WD Wagner","year":"1977","unstructured":"Wagner WD, Clarkson TB, Foster J. Contrasting effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on the regression of two types of dietary-induced atherosclerosis. Atherosclerosis. 1977;27(4):419\u201335. https:\/\/doi.org\/10.1016\/0021-9150(77)90161-7.","journal-title":"Atherosclerosis"},{"issue":"4515","key":"1364_CR76","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1126\/science.6792706","volume":"213","author":"DM Kramsch","year":"1981","unstructured":"Kramsch DM, Aspen AJ, Rozler LJ. Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science (New York, NY). 1981;213(4515):1511\u20132. https:\/\/doi.org\/10.1126\/science.6792706.","journal-title":"Science (New York, NY)"},{"key":"1364_CR77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bone.2013.12.017","volume":"61","author":"S Gonnelli","year":"2014","unstructured":"Gonnelli S, Caffarelli C, Tanzilli L, et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone. 2014;61:27\u201332. https:\/\/doi.org\/10.1016\/j.bone.2013.12.017.","journal-title":"Bone"},{"key":"1364_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12285","author":"Y Yang","year":"2017","unstructured":"Yang Y, Rong X, Lv X, et al. Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway. Cardiovasc Ther. 2017. https:\/\/doi.org\/10.1111\/1755-5922.12285.","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"1364_CR79","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/mmr.2013.1489","volume":"8","author":"S Zhou","year":"2013","unstructured":"Zhou S, Fang X, Xin H, et al. Effects of alendronate on the Notch1-RBP-J\u03ba signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells. Mol Med Rep. 2013;8(1):89\u201394. https:\/\/doi.org\/10.3892\/mmr.2013.1489.","journal-title":"Mol Med Rep"},{"issue":"3","key":"1364_CR80","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/jbmr.3660","volume":"34","author":"A Giollo","year":"2019","unstructured":"Giollo A, Rossini M, Gatti D, et al. Amino-bisphosphonates and cardiovascular risk: a new hypothesis involving the effects on gamma-delta T cells. J Bone Miner Res. 2019;34(3):570\u20131. https:\/\/doi.org\/10.1002\/jbmr.3660.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1364_CR81","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1006\/rtph.2002.1550","volume":"35","author":"M Steinbuch","year":"2002","unstructured":"Steinbuch M, D\u2019Agostino RB, Mandel JS, et al. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regulatory toxicology and pharmacology: RTP. 2002;35(3):320\u20136. https:\/\/doi.org\/10.1006\/rtph.2002.1550.","journal-title":"Regulatory toxicology and pharmacology: RTP"},{"issue":"18","key":"1364_CR82","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809\u201322. https:\/\/doi.org\/10.1056\/NEJMoa067312.","journal-title":"N Engl J Med"},{"issue":"18","key":"1364_CR83","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa074941.","journal-title":"N Engl J Med"},{"issue":"25","key":"1364_CR84","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379(25):2407\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1808082.","journal-title":"N Engl J Med"},{"issue":"1","key":"1364_CR85","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jbmr.3860","volume":"35","author":"IR Reid","year":"2020","unstructured":"Reid IR, Horne AM, Mihov B, et al. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. 2020;35(1):20\u20137. https:\/\/doi.org\/10.1002\/jbmr.3860.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1364_CR86","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.amjcard.2008.11.037","volume":"103","author":"TJ Bunch","year":"2009","unstructured":"Bunch TJ, Anderson JL, May HT, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. The American journal of cardiology. 2009;103(6):824\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2008.11.037.","journal-title":"The American journal of cardiology"},{"key":"1364_CR87","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.2779","author":"SR Cummings","year":"2019","unstructured":"Cummings SR, Lui L-Y, Eastell R, et al. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med. 2019. https:\/\/doi.org\/10.1001\/jamainternmed.2019.2779.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"1364_CR88","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118\u201324. https:\/\/doi.org\/10.1210\/jcem.85.11.6953.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1364_CR89","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/archinte.168.8.826","volume":"168","author":"SR Heckbert","year":"2008","unstructured":"Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168(8):826\u201331. https:\/\/doi.org\/10.1001\/archinte.168.8.826.","journal-title":"Arch Intern Med"},{"issue":"7648","key":"1364_CR90","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","volume":"336","author":"HT S\u00f8rensen","year":"2008","unstructured":"S\u00f8rensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (Clin Res ed). 2008;336(7648):813\u20136. https:\/\/doi.org\/10.1136\/bmj.39507.551644.BE.","journal-title":"BMJ (Clin Res ed)"},{"issue":"5","key":"1364_CR91","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2796.2008.02065.x","volume":"265","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009;265(5):581\u201392. https:\/\/doi.org\/10.1111\/j.1365-2796.2008.02065.x.","journal-title":"J Intern Med"},{"issue":"8","key":"1364_CR92","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365. https:\/\/doi.org\/10.1056\/NEJMoa0809493.","journal-title":"N Engl J Med"},{"issue":"2","key":"1364_CR93","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jbmr.2043","volume":"29","author":"EJ Samelson","year":"2014","unstructured":"Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29(2):450\u20137. https:\/\/doi.org\/10.1002\/jbmr.2043.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1364_CR94","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1113\/expphysiol.1991.sp003491","volume":"76","author":"LR Jordan","year":"1991","unstructured":"Jordan LR, Dallemagne CR, Cross RB. Cardiovascular effects of parathyroid hormone in conscious sheep. Exp Physiol. 1991;76(2):251\u20137. https:\/\/doi.org\/10.1113\/expphysiol.1991.sp003491.","journal-title":"Exp Physiol"},{"issue":"10117","key":"1364_CR95","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/s0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(17)32137-2.","journal-title":"Lancet"},{"key":"1364_CR96","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2147\/CIA.S107285","volume":"11","author":"A Nishikawa","year":"2016","unstructured":"Nishikawa A, Ishida T, Taketsuna M, et al. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report. Clin Interv Aging. 2016;11:913\u201325. https:\/\/doi.org\/10.2147\/CIA.S107285.","journal-title":"Clin Interv Aging"},{"issue":"7","key":"1364_CR97","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722\u201333. https:\/\/doi.org\/10.1001\/jama.2016.11136.","journal-title":"JAMA"},{"key":"1364_CR98","unstructured":"Final summary minutes of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting (January 16). Food and Drug Administration, Center for Drug Evaluation and Research. 2019."},{"key":"1364_CR99","unstructured":"Evenity: EPAR public assessment report. European Medicines Agency. 2019."},{"issue":"7","key":"1364_CR100","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, et al. FRAME Study: the foundation effect of building bone with 1\u00a0year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res. 2018;33(7):1219\u201326. https:\/\/doi.org\/10.1002\/jbmr.3427.","journal-title":"J Bone Miner Res"},{"issue":"16","key":"1364_CR101","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1607948.","journal-title":"N Engl J Med"},{"issue":"15","key":"1364_CR102","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1708322.","journal-title":"N Engl J Med"},{"key":"1364_CR103","doi-asserted-by":"publisher","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","volume":"130","author":"F Lv","year":"2020","unstructured":"Lv F, Cai X, Yang W, et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis. Bone. 2020;130:115121. https:\/\/doi.org\/10.1016\/j.bone.2019.115121.","journal-title":"Bone"},{"key":"1364_CR104","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Guideline update. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgaa048.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1364_CR105","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41574-018-0087-0","volume":"14","author":"NM Appelman-Dijkstra","year":"2018","unstructured":"Appelman-Dijkstra NM, Papapoulos SE. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. Nat Rev Endocrinol. 2018;14(10):605\u201323. https:\/\/doi.org\/10.1038\/s41574-018-0087-0.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"1364_CR106","doi-asserted-by":"publisher","first-page":"e19595","DOI":"10.1371\/journal.pone.0019595","volume":"6","author":"D Zhu","year":"2011","unstructured":"Zhu D, Mackenzie NC, Millan JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE. 2011;6(5):e19595. https:\/\/doi.org\/10.1371\/journal.pone.0019595.","journal-title":"PLoS ONE"},{"issue":"12","key":"1364_CR107","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1210\/jc.2015-3056","volume":"100","author":"P Evenepoel","year":"2015","unstructured":"Evenepoel P, Goffin E, Meijers B, et al. Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab. 2015;100(12):4669\u201376. https:\/\/doi.org\/10.1210\/jc.2015-3056.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1364_CR108","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/atvbaha.116.308723","volume":"37","author":"SM Krishna","year":"2017","unstructured":"Krishna SM, Seto SW, Jose RJ, et al. Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis. Arterioscler Thromb Vasc Biol. 2017;37(3):553\u201366. https:\/\/doi.org\/10.1161\/atvbaha.116.308723.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1364_CR109","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ajpath.2018.12.007","volume":"189","author":"B Javaheri","year":"2019","unstructured":"Javaheri B, Herbert E, Hopkinson M, et al. Sost haploinsufficiency provokes peracute lethal cardiac tamponade without rescuing the osteopenia in a mouse model of excess glucocorticoids. Am J Pathol. 2019;189(4):753\u201361. https:\/\/doi.org\/10.1016\/j.ajpath.2018.12.007.","journal-title":"Am J Pathol"},{"issue":"3","key":"1364_CR110","doi-asserted-by":"publisher","first-page":"e014170","DOI":"10.1161\/jaha.119.014170","volume":"9","author":"AL Kuipers","year":"2020","unstructured":"Kuipers AL, Miljkovic I, Barinas-Mitchell E, et al. Wnt pathway gene expression is associated with arterial stiffness. J Am Heart Assoc. 2020;9(3):e014170. https:\/\/doi.org\/10.1161\/jaha.119.014170.","journal-title":"J Am Heart Assoc"},{"key":"1364_CR111","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1038\/ncomms11505","volume":"7","author":"M Florio","year":"2016","unstructured":"Florio M, Gunasekaran K, Stolina M, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505. https:\/\/doi.org\/10.1038\/ncomms11505.","journal-title":"Nat Commun"},{"issue":"7","key":"1364_CR112","doi-asserted-by":"publisher","first-page":"e2917","DOI":"10.1038\/cddis.2017.277","volume":"8","author":"M Di","year":"2017","unstructured":"Di M, Wang L, Li M, et al. Dickkopf1 destabilizes atherosclerotic plaques and promotes plaque formation by inducing apoptosis of endothelial cells through activation of ER stress. Cell Death Dis. 2017;8(7):e2917. https:\/\/doi.org\/10.1038\/cddis.2017.277.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1364_CR113","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jbmr.2372","volume":"30","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chen NX, Newman CL, et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res. 2015;30(3):499\u2013509. https:\/\/doi.org\/10.1002\/jbmr.2372.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1364_CR114","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/jbmr.3036","volume":"32","author":"MS Ominsky","year":"2017","unstructured":"Ominsky MS, Boyd SK, Varela A, et al. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2017;32(4):788\u2013801. https:\/\/doi.org\/10.1002\/jbmr.3036.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1364_CR115","first-page":"139","volume":"4","author":"W Balemans","year":"2004","unstructured":"Balemans W, Van Hul W. Identification of the disease-causing gene in sclerosteosis\u2013discovery of a novel bone anabolic target? J Musculoskelet Neuronal Interact. 2004;4(2):139\u201342.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"1364_CR116","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","volume":"96","author":"AH van Lierop","year":"2017","unstructured":"van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE. Sclerostin deficiency in humans. Bone. 2017;96:51\u201362. https:\/\/doi.org\/10.1016\/j.bone.2016.10.010.","journal-title":"Bone"},{"issue":"3","key":"1364_CR117","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","volume":"63","author":"H Hamersma","year":"2003","unstructured":"Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;63(3):192\u20137. https:\/\/doi.org\/10.1034\/j.1399-0004.2003.00036.x.","journal-title":"Clin Genet"},{"issue":"3","key":"1364_CR118","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension study. J Bone Miner Res. 2019;34(3):419\u201328. https:\/\/doi.org\/10.1002\/jbmr.3622.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1364_CR119","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183\u201393. https:\/\/doi.org\/10.1210\/jc.2017-02163.","journal-title":"J Clin Endocrinol Metab"},{"key":"1364_CR120","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05379-z","author":"SR Cummings","year":"2020","unstructured":"Cummings SR, McCulloch C. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int. 2020. https:\/\/doi.org\/10.1007\/s00198-020-05379-z.","journal-title":"Osteoporos Int"},{"key":"1364_CR121","unstructured":"Approval of the marketing authorisation for Evenity (romosozumab): re-examination leads to recommendation to approve. 2019."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01364-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01364-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01364-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T19:13:28Z","timestamp":1627413208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01364-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":121,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01364-2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738406984.793584761","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"28 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The ESCEO Working Group was funded by the ESCEO. The ESCEO receives unrestricted educational grants to support its educational and scientific activities from non-governmental organisations, not-for-profit organisations, non-commercial or corporate partners. The choice of topics, participants, content and agenda of the Working Groups as well as the writing, editing, submission and reviewing of the manuscript are the sole responsibility of the ESCEO, without any influence from third parties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NRF, AC, JMK, NA, CC have nothing to disclose. FT reports personal fees for lectures and expertise from Amgen, Arrow, Lilly France, TEVA and Theramex and non-financial support from Besins Healthcare France. MLB reports honoraria from Amgen, Bruno Farmaceutici, Calcilytix and Kyowa Kirin, academic grants and\/or speaker fees from Abiogen, Alexion, Amgen, Bruno Farmaceutici, Eli Lilly, Kyowa Kirin, MSD, NPS Pharma, Servier, Shire and Spa and consultancy work for Alexion, Bruno Farmaceutici, Kyowa Kirin, Servier and Shire. SR reports advisory board participation, consultancy work, speakers\u2019 fees and research grants from Mylan, Abbot, Amgen, Ceres and Gilead. NCH reports consultancy work and lecture fees and honoraria from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma. DPA\u2019s research group has received research grants from Amgen, Servier and UCB and speaker tuition fees and advisory or consultancy fees (all paid to his department) from Amgen and UCB. TT reports personal fees for lectures and expertise from Amgen, Arrow, Biogen, BMS, Chugai, Expanscience, Gilead, Grunenthal, LCA, Lilly, Medac, MSD, Nordic, Novartis, Pfizer, Sandoz, Sanofi, Theramex, Thuasne, TEVA and UCB and reports financial support or fees for research activities from Amgen, Bone Therapeutics, Chugai, MSD, Novartis, Pfizer and UCB. EMD reports consultancy fees for UCB and Pfizer. JAK reports institutional grant support from Radius Health and Amgen. JYR reports consulting fees or advisory board participation for IBSA-Genevrier, Mylan, Radius Health and Pierre Fabre, lecturing fees for IBSA-Genevrier, Mylan, Cniel and Dairy Research Council (DRC) and grant support from IBSA-Genevrier, Mylan, Cniel and Radius Health. RR reports speaker fees from Abiogen, Amgen, EMF and Sandoz and advisory board fees from Echolight, Mylan, ObsEva, Rejuvenate and Theramex. OB reports grants from Biophytis, IBSA, MEDA, Servier and SMB and personal fees from Amgen, Aptissen, Biophytis, IBSA, MEDA, Sanofi, Servier, SMB and UCB. ADP reports speaker and advisory fees from Amgen, Lilly, Theramex, UCB and Sandoz.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}